Skip to content

Biomarkers in Acute Cardiac Care

Biomarkers in Acute Cardiac Care

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02355457
Acronym
BACC
Enrollment
5000
Registered
2015-02-04
Start date
2013-07-31
Completion date
2027-12-31
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome, Chest Pain, Myocardial Infarction

Keywords

troponin, myocardial infarction, acs, AMI, biomarker, BACC, high-sensitivity

Brief summary

The primary aim of the study is to investigate new cardiac biomarkers and algorithms to diagnose acute coronary syndrome in patients with suspected acute myocardial infarction.

Detailed description

The primary aim of the study is to detect and evaluate new cardiac biomarkers, evaluate and improve acute coronary syndrome (ACS) risk scores, which takes into account clinical, gender specific, psycho-social and lifestyle-risk factors, protein patterns and genetic variability in addition to the classical risk factors with respect to the primary endpoint of acute myocardial infarction. Secondary study aims are : * To provide estimates for the incidence of ACS in patients presenting with recent onset chest pain; * To provide accurate, quantifiable measures of precursors of ACS; * DNA, RNA, cells, and serum/plasma for comprehensive genetic, gene expression and proteomic studies * To explore the impact of ACS candidate genes on cardiovascular risk stratification by using genome-wide analyses and a biological systems approach; * To explore proteins relevant for ACS; * To allow the identification of new therapeutic targets; * To evaluate the impact of socio-economic factors on ACS and CAD risk. Patients will be followed up during the hospital stay. Afterwards a telephone follow-up will take place after 30 days, 6, 24 and 48 months.

Interventions

None listed

Sponsors

Universitätsklinikum Hamburg-Eppendorf
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Symptoms suggestive of acute myocardial infarction * Ability to provide written informed consent in accordance with Good epidemiological Practice and local legislation * Individuals at least 18 years old

Exclusion criteria

\- Insufficient knowledge of the German language (able to understand and write the German language)

Design outcomes

Primary

MeasureTime frameDescription
Acute myocardial infarction as index eventMonthsThe primary endpoint of the study is acute myocardial infarction

Secondary

MeasureTime frameDescription
AMI, Mortality, heart failure and quality of lifeYearsThe secondary endpoint of the study is mortality, heart failure, quality of life.

Countries

Germany

Contacts

Primary ContactJohannes T Neumann, MD
j.neumann@uke.de0049407410
Backup ContactNils Sörensen, MD
n.soerensen@uke.de0049407410

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 22, 2026